[(4-benzyloxy)benzyl]triphenylphosphonium chloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [(4-benzyloxy)benzyl]triphenylphosphonium chloride
• 英文别名: (4-benzyloxybenzyl)triphenylphosphonium chloride；triphenyl(4-benzyloxybenzyl)phosphonium chloride；[4-(benzyloxy)benzyl](triphenyl)phosphonium chloride；4-benzyloxybenzyltriphenyl phosphonium chloride；4-benzyloxybenzyltriphenylphosphonium chloride；4-Benzyloxy-benzyltriphenylphosphonium；triphenyl-[(4-phenylmethoxyphenyl)methyl]phosphanium;chloride
• 化学式: C₃₂H₂₈OP*Cl
• 分子量: 495.0
• InChiKey: ZNDBERRZILXTHK-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  3.76
• 重原子数：
  35
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  [(4-benzyloxy)benzyl]triphenylphosphonium chloride 在 palladium on activated charcoal ammonium hydroxide 、 sodium hydroxide 、 草酰氯 、 氢气 、 sodium hydride 、 N,N-二甲基甲酰胺 、 三苯基膦 、 三氟乙酸 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 272.25h， 生成 [(6RS)-6-[2-[4-[[(3S)-3-pyrrolidinyl]oxy]phenyl]ethyl]-5,6,7,8-tetrahydro-2-naphthyl]carboxamide
  参考文献：
  名称：

  Design, synthesis, and biological activity of non-basic compounds as factor Xa inhibitors: SAR study of S1 and aryl binding sites

  摘要：

  Compound 7 was identified as the active metabolite of 6 by HPLC and mass spectral analysis. Modification of lead compound 7 by transformation of its N-oxide 6-6 biaryl ring system and fused aromatics produced a series of non-basic fxa inhibitors with excellent potency in anti-fXa and anticoagulant assays. The optimized compounds 73b and 75b showed sub to one digit micromolar anticoagulant activity (PTCT2). Particularly, anti-fXa activity was detected in plasma of rats orally administered with 1 mg/kg of compound 75b. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.04.006
• 作为产物：
  描述：

  4-苄氧基苄醇 在 氯化亚砜 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 1.0h， 生成 [(4-benzyloxy)benzyl]triphenylphosphonium chloride
  参考文献：
  名称：

  苯并呋喃类化合物及其制备、用途

  摘要：

  本发明涉及一种苯并呋喃类化合物及其制备、用途，其结构式如式(I)所示：其中，R1、R2、R4分别选自氢、C1‑C5的烷基、硝基、卤素、酯基、羟基、氨基、酰胺基或烷氧基；R3为氢、C1‑C5的烷基、苄基、芳香基或杂芳香基。本发明还涉及所述苯并呋喃化合物在抑制革兰氏阳性菌上的应用。本发明以3‑酮肟取代基苯并呋喃结构芳环为中心，建立和优化化合物的制备方法，并对制备的新型化合物进行抑菌筛选实验，通过初步抑菌试验确认所制备的化合物具有广谱的抑菌活性。

  公开号：

  CN104478836B

文献信息

• FIVE-MEMBERED HETEROCYCLIC COMPOUNDS
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1541564A1

  公开（公告）日：2005-06-15

  The present invention provides a compound represented by the formula: wherein R1 is an optionally substituted 5-membered heterocyclic group; X, Y and V are the same or different and each is a bond, an oxygen atom, a sulfur atom and the like; Q is a divalent hydrocarbon group having 1 to 20 carbon atoms; ring A is an aromatic ring optionally further having 1 to 3 substituents; Z is -(CH2)n-Z1- or -Z1-(CH2)n- (n is an integer of 0 to 8, Z1 is a bond, an oxygen atom, a sulfur atom and the like); ring B is a nitrogen-containing heterocycle optionally further having 1 to 3 substituents; W is a bond or a divalent hydrocarbon group having 1 to 20 carbon atoms; R2 is a hydrogen atom, a cyano group, -PO(OR9)(OR10) (R9 and R10 are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, and R9 and R10 are optionally bonded to form an optionally substituted ring) and the like, or a salt thereof, which has a superior adipose tissue weight decreasing action, a hypoglycemic action and a hypolipidemic action, and which is useful as an agent for the prophylaxis or treatment of obesity, diabetes mellitus, hyperlipidemia, impaired glucose tolerance, hypertension and the like.

  本发明提供了一种由以下式表示的化合物： 其中R1是可选择地取代的5-成员杂环基团；X、Y和V相同或不同，每个都是键，氧原子，硫原子等；Q是具有1到20个碳原子的二价碳氢基团；环A是一个芳香环，可选择地进一步具有1到3个取代基；Z是-(CH2)n-Z1-或-Z1-(CH2)n-（n是0到8的整数，Z1是键，氧原子，硫原子等）；环B是一个含氮杂环，可选择地进一步具有1到3个取代基；W是键或具有1到20个碳原子的二价碳氢基团；R2是氢原子，氰基，-PO(OR9)(OR10)（R9和R10相同或不同，每个是氢原子或可选择地取代的碳氢基团，R9和R10可选择地结合形成可选择地取代的环）等，或其盐，具有优越的减少脂肪组织重量的作用，降糖作用和降脂作用，并且作为预防或治疗肥胖症，糖尿病，高脂血症，糖耐量受损，高血压等的药剂是有用的。
• Synthesis and Structural Reassignment of Plakinidone
  作者：Ze-Jun Xu、Dong-Xing Tan、Yikang Wu

  DOI：10.1021/acs.orglett.5b02599

  日期：2015.10.16

  In connection with its first synthesis, plakinidone was structurally revised to a five-membered lactone. The key evidence for the previous assignment of this natural product as a perlactone was proven to be a misinterpretation of the MS data because of unawareness of a facile air oxidation. The synthetic samples also allowed for detection of differences in 13C NMR for diastereomers of remote stereogenic

  在其首次合成过程中，将plakinidone结构上修改为五元内酯。以前将该天然产物指定为过内酯的关键证据被证明是对MS数据的误解，因为它不知道容易的空气氧化作用。合成样品还允许检测遥远的立体成因中心的非对映异构体的13 C NMR差异，以及空气氧化对旋光性的影响。
• Determination of the binding mode and interacting amino-acids for dibasic H3 receptor antagonists
  作者：Nicolas Levoin、Olivier Labeeuw、Stéphane Krief、Thierry Calmels、Olivia Poupardin-Olivier、Isabelle Berrebi-Bertrand、Jeanne-Marie Lecomte、Jean-Charles Schwartz、Marc Capet

  DOI：10.1016/j.bmc.2013.05.035

  日期：2013.8

  the range of modern drug discovery tools, such as receptor modeling and ligand docking. Although the receptor models described to date share a majority of common traits, they display discrete alternatives in amino-acid conformation, rendering ligand binding modes quite different. Such variations impede structure-based drug design in the H3R field. In the present study, we used a combination of medicinal

  由于组胺H3受体（CN3）参与主要的CNS功能，因此它是深入的药物化学研究的主题，并得到一系列现代药物发现工具的支持，例如受体建模和配体对接。尽管迄今为止描述的受体模型具有大多数共同特征，但它们在氨基酸构象上显示出离散的替代方案，从而使配体结合模式完全不同。这种变化阻碍了H3R领域中基于结构的药物设计。在本研究中，我们结合了药物化学，受体指导和基于配体的方法来阐明拮抗剂的结合方式。这些方法朝着垂直于膜平面的配体方向汇聚，将跨膜螺旋5的Glu206与细胞外环的酸性氨基酸桥接。
• [EN] BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR<br/>[FR] DÉRIVÉ DE BENZÈNE OU DE THIOPHÈNE ET SON UTILISATION EN TANT QU'INHIBITEUR DE LA VAP-1
  申请人：R TECH UENO LTD

  公开号：WO2009145360A1

  公开（公告）日：2009-12-03

  The present invention provides a novel benzene derivative or thiophene derivative useful as a VAP-1 inhibitor, or a medicament for the prophylaxis or treatment of a VAP-1 associated disease and the like, namely, a compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种新颖的苯衍生物或噻吩衍生物，可用作VAP-1抑制剂，或用作预防或治疗与VAP-1相关的疾病等的药物，即由以下式（I）表示的化合物：其中每个符号如本说明书中所定义，或其药学上可接受的盐。
• Chemical structure and sweet taste of isocoumarin and related compounds. IX.
  作者：MASATOSHI YAMATO、KOICHI SATO、KUNIKO HASHIGAKI、TAKAJI KOYAMA

  DOI：10.1248/cpb.25.706

  日期：——

  Structural modification of the phenyl moiety (A moiety) of β-(3-hydroxy-4-methoxyphenyl) ethylbenzene (I), which constitute an essential part of phyllodulcin molecules, was attempted to make the relationship between structure and sweet taste clearer. Twenty-four derivatives of A moiety of I were synthesized, the compound (II, IV, V, VI, X, XXII, XXIII, and XXVI) revealed sweet taste and the other compounds were tasteless. On the basis of these data, the taste of these compounds were discussed in connection with the stereochemical hindrance effect of substituents.

  对β-(3-羟基-4-甲氧基苯基)乙基苯（I）的苯基部分（A部分）进行了结构修饰，试图使结构与甜味之间的关系更加明确。合成了I的24种A部分衍生物，其中化合物（II、IV、V、VI、X、XXII、XXIII和XXVI）显示出甜味，而其他化合物则无味。根据这些数据，讨论了这些化合物的味道与取代基的立体化学障碍效应之间的关系。